On August 23, Johnson & Johnson (J&J) issued a written notice to disproportionate share hospitals that participate in the prescription drug discount program established under section 340B of the federal Public Health Service Act, advising them that, beginning on October 15, it would no longer offer 340B discounts at the time of purchase on two of its drugs, the plaque psoriasis drug Stelara and the blood thinner Xarelto….
By: Manatt, Phelps & Phillips, LLP
By: Manatt, Phelps & Phillips, LLP
